Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 17/20 | 0.60 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.56 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.55 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.52 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.52 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.52 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR2C | P28335 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL32666146 | 1.00 | S1PR1 (0.60) | S1PR1MAPKAPK2SIRT1S1PR4ADORA3 | |
| SCHEMBL30762322 | 1.00 | S1PR1 (0.60) | S1PR1MAPKAPK2SIRT1S1PR4ADORA3 | |
| SCHEMBL29141420 | 1.00 | S1PR1 (0.60) | S1PR1MAPKAPK2SIRT1S1PR4ADORA3 | |
| SCHEMBL9459050 | 0.92 | SIRT1 (0.62) | S1PR1MAPKAPK2SIRT1S1PR4ADORA3 | |
| SCHEMBL25147653 | 0.86 | SIRT1 (0.60) | S1PR1SIRT1 | |
| SCHEMBL29141416 | 0.86 | S1PR1 (0.59) | S1PR1MAPKAPK2S1PR4ADORA3S1PR5 | |
| SCHEMBL30762323 | 0.86 | SIRT1 (0.60) | S1PR1SIRT1 | |
| SCHEMBL5421567 | 0.86 | S1PR1 (0.59) | S1PR1MAPKAPK2S1PR4ADORA3S1PR5 | |
| SCHEMBL5088953 | 0.86 | S1PR1 (0.59) | S1PR1MAPKAPK2S1PR4ADORA3S1PR5 | |
| SCHEMBL30762321 | 0.86 | SIRT1 (0.60) | S1PR1SIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117430547-A | Preparation method of single enantiomer of tetrahydrocyclopenta [ b ] indol-3-yl acetic acid and derivative thereof | 安徽艾立德制药有限公司 | 2024-01-23 | — | — | CN | disclosed |
| US-20170159088-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. | 2017-06-08 | — | — | US | disclosed |
| US-9447041-B2 | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2016-09-20 | — | — | US | disclosed |
| US-20160016904-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2016-01-21 | — | — | US | disclosed |
| US-9175320-B2 | Processes for the preparation of (R)-2-(7-4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[B]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2015-11-03 | — | — | US | disclosed |
| US-20140357690-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2014-12-04 | — | — | US | disclosed |
| US-8853419-B2 | Processes for the preparation of (R)-2-(7-(4-cyclopentyl-3-(trifluoromethyl)benzyloxy)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid and salts thereof | ARENA PHARMACEUTICALS, INC. (US) | 2014-10-07 | — | — | US | disclosed |
| EP-2528894-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | Arena Pharmaceuticals, Inc. (US) | 2012-12-05 | — | — | EP | disclosed |
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2012-11-22 | — | — | US | disclosed |
| WO-2011094008-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
| WO-2011094008-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | ARENA PHARMACEUTICALS, INC. (US) | 2011-08-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120295947-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885MAPKAPK2 1897/4885SIRT1 1984/4885 |
| US-20140357690-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885MAPKAPK2 1897/4885SIRT1 1984/4885 |
| US-20170159088-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885MAPKAPK2 1897/4885SIRT1 1984/4885 |
| US-20160016904-A1 | PROCESSES FOR THE PREPARATION OF (R)-2-(7-(4-CYCLOPENTYL-3-(TRIFLUOROMETHYL)BENZYLOXY)-1,2,3,4-TETRAHYDROCYCLOPENTA[B]INDOL-3-YL)ACETIC ACID AND SALTS THEREOF | S1PR1, S1PR5, S1PR2 | S1PR1 1/4885MAPKAPK2 1929/4885SIRT1 1884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.